Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 12Dermatologic 2CNS 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1NET 1Lymphoid 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms 1310Carcinoma, Renal Cell 661Urinary Bladder Neoplasms 405Carcinoma, Non-Small-Cell Lung 334Neoplasms 301Carcinoma, Transitional Cell 264Breast Neoplasms 252Ovarian Neoplasms 248Melanoma 235Colorectal Neoplasms 228Neoplasm Metastasis 214Kidney Neoplasms 200Pancreatic Neoplasms 169Stomach Neoplasms 162Squamous Cell Carcinoma of Head and Neck 143Lung Neoplasms 140Uterine Cervical Neoplasms 123Non-Muscle Invasive Bladder Neoplasms 118Triple Negative Breast Neoplasms 112Head and Neck Neoplasms 111Endometrial Neoplasms 109Esophageal Neoplasms 107Carcinoma, Hepatocellular 98Small Cell Lung Carcinoma 80Sarcoma 75Colonic Neoplasms 55Urologic Neoplasms 53Prostatic Neoplasms, Castration-Resistant 47Liver Neoplasms 47Cholangiocarcinoma 43

Interventions

pasireotide 1Cabergoline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Pituitary Neoplasms × Genitourinary × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡